Lewy Body Dementia Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Lewy Body Dementia pipeline constitutes key companies continuously working towards developing Lewy Body Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Lewy Body Dementia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Lewy Body Dementia Pipeline Insight, 2026 [https://www.delveinsight.com/sample-request/lewy-body-dementia-lbd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lewy Body Dementia Market.

Some of the key takeaways from the Lewy Body Dementia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Lewy Body Dementia treatment therapies with a considerable amount of success over the years.

*
Lewy Body Dementia companies working in the treatment market are Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc, and others, are developing therapies for the Lewy Body Dementia treatment

*
Emerging Lewy Body Dementia therapies in the different phases of clinical trials are- E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others are expected to have a significant impact on the Lewy Body Dementia market in the coming years.

*
In March 2026, Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, today announced its financial results for the fourth quarter and the full year ending December 31, 2025. The company's management will hold a live webcast conference call at 8:30 a.m. ET to discuss these results and share updates on the clinical development of zervimesine (CT1812) for dementia with Lewy bodies (DLB) and Alzheimer's disease.

*
In July 2025, Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company focused on developing therapies for neurodegenerative disorders, announced that Dr. James E. Galvin, MD, MPH, will present findings from the Phase 2 'SHIMMER' study evaluating zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral session at the Alzheimer's Association International Conference (AAIC). Dr. Galvin, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, also served as the study director for the COG1201 SHIMMER trial (NCT05225415).

*
In March 2025, CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biopharmaceutical company developing therapies for age-related neurological disorders, reported encouraging results from the initial 16 weeks of the extension phase of its Phase 2b RewinD-LB study, evaluating neflamapimod for the treatment of dementia with Lewy bodies (DLB).

*
In December 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, announced topline results from the exploratory Phase 2 'SHIMMER' study. The findings revealed that CT1812 showed significant therapeutic benefits across behavioral, functional, cognitive, and motor assessments in patients with dementia with Lewy bodies (DLB).

Lewy Body Dementia Overview

Lewy Body Dementia (LBD) is a progressive brain disorder characterized by abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, known as Lewy bodies, affect chemicals in the brain and can lead to problems with thinking, movement, behavior, and mood. LBD encompasses two related conditions: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD).

Get a Free Sample PDF Report to know more about Lewy Body Dementia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/lewy-body-dementia-lbd-pipeline-insight [https://www.delveinsight.com/report-store/lewy-body-dementia-lbd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Lewy Body Dementia Drugs Under Different Phases of Clinical Development Include:

*
E2027: Eisai

*
Neflamapimod: EIP Pharma

*
K0706: Sun Pharma

*
RVT-101: Axovant Sciences Ltd.

*
CT1812: Cognition Therapeutics

*
K0706: Cephalon

*
Irsenontrine: Eisai Inc.

*
Neflamapimod: EIP Pharma Inc

*
Donepezil: Eisai Co., Ltd.

*
ATH-1017: Athira Pharma

*
Galantamine: Ortho-McNeil Neurologics, Inc.

*
Memantine: H. Lundbeck A/S

*
Nelotanserin: Axovant Sciences Ltd.

*
DatSCAN: GE Healthcare

*
NYX-458: Aptinyx

*
N-831(Traneurocin): NeuroActiva, Inc.

*
CST-103, CST-107: CuraSen Therapeutics, Inc.

*
Pimavanserin: ACADIA Pharmaceuticals Inc.

Lewy Body Dementia Pipeline Therapeutics Assessment

*
Lewy Body Dementia Assessment by Product Type

*
Lewy Body Dementia By Stage and Product Type

*
Lewy Body Dementia Assessment by Route of Administration

*
Lewy Body Dementia By Stage and Route of Administration

*
Lewy Body Dementia Assessment by Molecule Type

*
Lewy Body Dementia by Stage and Molecule Type

DelveInsight's Lewy Body Dementia Report covers around products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Lewy Body Dementia product details are provided in the report. Download the Lewy Body Dementia pipeline report to learn more about the emerging Lewy Body Dementia therapies [https://www.delveinsight.com/sample-request/lewy-body-dementia-lbd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Lewy Body Dementia Therapeutics Market include:

Key companies developing therapies for Lewy Body Dementia are - Jazz Pharmaceuticals Inc., Allergan Plc., Noven Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, BioArctic AB, Sumitomo Pharma Co. Ltd., Novartis AG, GSK Plc., and others.

Lewy Body Dementia Pipeline Analysis:

The Lewy Body Dementia pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Lewy Body Dementia with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lewy Body Dementia Treatment.

*
Lewy Body Dementia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Lewy Body Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lewy Body Dementia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Lewy Body Dementia drugs and therapies [https://www.delveinsight.com/sample-request/lewy-body-dementia-lbd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Lewy Body Dementia Pipeline Market Strengths

*
Increasing research and development to understand the diversity of the disease might improve the diagnosis of LBD thereby resulting in a lucrative market opportunity.

*
Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Lewy Body Dementia Pipeline Market Opportunities

*
Several organizations are actively working to provide information and increase awareness of such disorders.

*
There is only one approved treatment option for LBD which opens a platform of new therapies to boost the market ofLBD.

*
The pipeline for PMM is narrow as there is limited R&D activity

Scope of Lewy Body Dementia Pipeline Drug Insight

*
Coverage: Global

*
Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc, and others

*
Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others

*
Lewy Body Dementia Therapeutic Assessment: Lewy Body Dementia current marketed and Lewy Body Dementia emerging therapies

*
Lewy Body Dementia Market Dynamics: Lewy Body Dementia market drivers and Lewy Body Dementia market barriers

Request for Sample PDF Report for Lewy Body Dementia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/lewy-body-dementia-lbd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Lewy Body Dementia Report Introduction

2. Lewy Body Dementia Executive Summary

3. Lewy Body Dementia Overview

4. Lewy Body Dementia- Analytical Perspective In-depth Commercial Assessment

5. Lewy Body Dementia Pipeline Therapeutics

6. Lewy Body Dementia Late Stage Products (Phase II/III)

7. Lewy Body Dementia Mid Stage Products (Phase II)

8. Lewy Body Dementia Early Stage Products (Phase I)

9. Lewy Body Dementia Preclinical Stage Products

10. Lewy Body Dementia Therapeutics Assessment

11. Lewy Body Dementia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Lewy Body Dementia Key Companies

14. Lewy Body Dementia Key Products

15. Lewy Body Dementia Unmet Needs

16 . Lewy Body Dementia Market Drivers and Barriers

17. Lewy Body Dementia Future Perspectives and Conclusion

18. Lewy Body Dementia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lewy-body-dementia-pipeline-2026-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-jazz-pharma-allergan-noven-pharma-takeda-pharma-eli-lilly-mallinckrodt-pharma]
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.